Disease-modifying treatments for rare kidney diseases
Walden Biosciences is developing first-in-class medicines designed to stop the progression of proteinuric chronic kidney diseases (CKD) by inhibiting the underlying mechanisms that lead to proteinuria.
explore our programs
Our commitment to rare CKD
Despite available treatment, a substantial proportion of patients with rare CKD progress to end-stage kidney disease. Walden is applying unique, multi-disciplinary approaches designed to prevent kidney damage and stop disease progression.
Our clinical trials
We are currently conducting a Phase 2 clinical study of WAL0921 at over 50 locations spanning seven countries. WAL0921 is a humanized monoclonal antibody that inhibits the pathological activity of soluble and cell surface-bound urokinase plasminogen activator receptor (suPAR/uPAR). This investigational treatment has the potential to be the first disease-modifying drug for the treatment of proteinuric CKD.
